ArticleFrontiers in immunology2026
Unlocking HER2 as a target in KRAS-mutated rectal cancer: a case of significant response to zanidatamab-based regimen.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Colorectal cancer (CRC) with human epidermal growth factor receptor 2 (HER2) overexpression and RAS mutations is often associated with poor response to conventional treatments, presenting substantial therapeutic challenges. This report describes a remarkable response in a patient with HER2-amplified, KRAS-mutated metastatic rectal cancer, who was treated with a zanidatamab-based combination regimen. Case presentation: A 54-year-old male was admitted to our hospital complaining of hematochezia and was diagnosed with rectal adenocarcinoma via biopsy. Baseline imaging revealed extensive, unresectable liver metastases. Next-generation sequencing identified a KRAS G12D mutation alongside HER2 amplification. Although the combination of chemotherapy and bevacizumab yielded promising efficacy, but tumor markers still remained high. When the anti-HER2 bispecific antibody zanidatamab was added, after three cycles of this triplet therapy, the liver metastases exhibited radiographic regression, and tumor markers showed substantial decline. The patient achieved sufficient downstaging and subsequently underwent successful hepatic resection. Pathological examination confirmed negative surgical margins. Conclusion: This case underscores the potential of HER2 inhibition as an effective therapeutic strategy in KRAS-mutated CRC. It also highlights zanidatamab's promise as part of a conversion therapy approach in patients with historically refractory disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.